The fourth round of Seed Funding opened for competitive applications on 4 February 2021 and closed on 14 April 2021.  A total of 23 applications were received, three were deemed ineligible by the Chair for being out of scope.  Twenty applications were viewed by the WG and the top 10 were reviewed by the WG on 11 May 2021. The working group recommended that 6 applications be funded, and this was ratified by the Board at their meeting on 17 May 2021.

Total grant funding awarded in Round 4 Seed Funding was $459,950.78.

Integrating contingency management for methamphetamine use into routine clinical care in Australia

Amount awarded: $86,109.00

Principal Investigator: A/Prof Rebecca McKetin, University of New South Wales.

Feasibility and preliminary efficacy of Cognitive Remediation Groups in a community outpatient setting for people who use methamphetamines.

Amount awarded: $74,738.00

Principal Investigator: A/Prof Peter Kelly, University of Wollongong.

Theta burst Transcranial Magnetic Stimulation (TMS) for Methamphetamine use disorder– A feasibility study to inform the design of a multisite randomised control trial.

Amount awarded: $100,000.00

Principal Investigator: Dr Buddhima Lokuge & Dr. Tarun Yadav, Hunter New England Local Health District

Cannabidiol – A novel pharmacotherapy for Lowering Methamphetamine use (The CALM Study)

Amount awarded: $99,408.00

Principal Investigator: Dr Gill Bedi, Orygen National.

Examining the effects of Amphetamine-Type-Substance use on clinical outcomes among clients receiving opioid agonist treatment

Amount awarded: $42,536.78

Principal Investigator: Dr Llewellyn Mills, South Eastern Sydney Local Health District

Co-designing a fixed-site drug checking service at Sydney’s Medically Supervised Injecting Centre (MSIC)

Amount awarded: $57,159.00

Principal Investigator: Dr Robert Page, The Loop Australia / University of New South Wales.